We Are Publishing Too Many Conference Proceedings

As an editor, I find that book buyers dislike conference volumes more than any other category of book, and yet the partnership of scientists and publishers persists in producing them. How are we to explain the fact that scientists can be both disdainful and enthusiastic about these ephemeral publications? What is it that drives the community to support proceedings volumes at all? Can we afford to do without them? Last August, I attended the Twentieth General Assembly of the International Astro

Written bySimon Mitton
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Last August, I attended the Twentieth General Assembly of the International Astronomical Union (IAU) in Baltimore, which lasted 11 days. Nearly 2,000 astronomers registered and participated in half a dozen parallel sessions. In addition, there were 10 or so satellite symposia and discussion meetings before and after the General Assembly. I estimate that the publications of all these meetings will require about 8,000 pages and the resources of at least four publishers. The total cost to any library that takes everything will not leave much change from $1,000. Worldwide we are talking about $500,000 of library funds to put the printed versions of this one scientific assembly on the shelves.

There is nothing special about astronomers in all of this; exactly the same sorts of meetings and their associated publications are found in chemistry, computer science, and molecular biology. What concerns me is that too much material is being produced ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies